586 related articles for article (PubMed ID: 26119560)
1. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
[TBL] [Abstract][Full Text] [Related]
2. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.
Watanabe E; Matsuyama H; Matsuda K; Ohmi C; Tei Y; Yoshihiro S; Ohmoto Y; Naito K
Cancer Immunol Immunother; 2003 Aug; 52(8):481-6. PubMed ID: 12707736
[TBL] [Abstract][Full Text] [Related]
3. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
4. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
Jackson AM; Ivshina AV; Senko O; Kuznetsova A; Sundan A; O'Donnell MA; Clinton S; Alexandroff AB; Selby PJ; James K; Kuznetsov VA
J Urol; 1998 Mar; 159(3):1054-63. PubMed ID: 9474231
[TBL] [Abstract][Full Text] [Related]
6. Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer.
Rigaud J; Leger A; Devilder MC; Bouchot O; Bonneville M; Scotet E
Clin Genitourin Cancer; 2015 Aug; 13(4):e209-e215. PubMed ID: 25735197
[TBL] [Abstract][Full Text] [Related]
7. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
8. [Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].
Krajewski W; Kołodziej A; Dembowski J; Zdrojowy R
Postepy Hig Med Dosw (Online); 2014 Mar; 68():291-300. PubMed ID: 24662797
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guérin treat interstitial cystitis by altering the immune profile in the bladder?
Peters KM; Diokno AC; Steinert BW
Urology; 1999 Sep; 54(3):450-3. PubMed ID: 10475352
[TBL] [Abstract][Full Text] [Related]
12. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?
de Reijke TM; De Boer EC; Kurth KH; Schamhart DH
J Urol; 1999 Jan; 161(1):67-71. PubMed ID: 10037371
[TBL] [Abstract][Full Text] [Related]
13. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
[TBL] [Abstract][Full Text] [Related]
14. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
17. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
[TBL] [Abstract][Full Text] [Related]
18. Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer.
Salmasi A; Elashoff DA; Guo R; Upfill-Brown A; Rosser CJ; Rose JM; Giffin LC; Gonzalez LE; Chamie K
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1036-1044. PubMed ID: 30593457
[TBL] [Abstract][Full Text] [Related]
19. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
[TBL] [Abstract][Full Text] [Related]
20. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
